Antiplaquettaires et transfusion

  title={Antiplaquettaires et transfusion},
  author={Pascale Gaussem and Anne-C{\'e}line Martin and Tiphaine Belleville-Rolland and Dominique Helley and Christilla Bachelot-Loza and Anne Godier},
  journal={Transfusion Clinique Et Biologique},
2 Citations


Structural and functional characterization of a specific antidote for ticagrelor.
The identification and the in vitro and in vivo pharmacology of an antigen-binding fragment (Fab) antidote for ticagrelor were presented and this specific antidote may prove valuable as an agent for patients who require emergency procedures.
Ticagrelor reversal: in vitro assessment of four haemostatic agents
In vitro the efficacy of four haemostatic drugs, namely recombinant activated factor VII (rFVIIa), fibrinogen concentrate (Fib), tranexamic acid (TXA) and factor XIII concentrate (FXIII) to improve the haemOSTatic capacity in the presence of ticagrelor is investigated.
Tranexamic acid partially improves platelet function in patients treated with dual antiplatelet therapy
The results of this study indicate that tranexamic acid potentially corrects defects in arachidonic acid-induced and ADP-induced platelet aggregation imposed by dual antiplatelet therapy, and support the use of tranExamic acid to partially reverse platelets aggregation dysfunction due to antiplatelets therapy.
The effectiveness of platelet supplementation for the reversal of ticagrelor-induced inhibition of platelet aggregation: An in-vitro study
The results do not support the use of platelet transfusion to reverse the effects of ticagrelor, and platelet supplementation restored platelet aggregation in aspirin-spiked but not in ticgrelor-sp spiked samples.
Platelet function recovery after ticagrelor withdrawal in patients awaiting urgent coronary surgery
  • E. Hansson, C. Malm, A. Jeppsson
  • Medicine
    European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • 2017
Adenosine diphosphate-induced aggregation was acceptable after 72 h in the majority of patients but with a large interindividual variability, platelet function testing may prove to be a valuable tool in timing of surgery in patients with ongoing or recently stopped ticagrelor treatment.
No Benefit From Platelet Transfusion for Gastrointestinal Bleeding in Patients Taking Antiplatelet Agents
  • L. Zakko, T. Rustagi, M. Douglas, L. Laine
  • Medicine
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2017
Efficacy of Ex Vivo Autologous and In Vivo Platelet Transfusion in the Reversal of P2Y12 Inhibition by Clopidogrel, Prasugrel, and Ticagrelor: The APTITUDE Study
PT restores platelet reactivity in patients with acute coronary syndrome/percutaneous coronary intervention and in patients undergoing cardiac surgery on P2y12 RI while bleeding with a less effect with increasing potency of P2Y12 inhibition.
Effect of acetylsalicylic acid usage and platelet transfusion on postoperative hemorrhage and activities of daily living in patients with acute intracerebral hemorrhage.
Transfusion of previously frozen apheresis platelets reduces the rate of postoperative hemorrhage, average postoperatively hemorrhage volume, disability rate, and mortality rate in ASA-sensitive patients with acute hypertensive basal ganglia hemorrhage undergoing craniotomy.
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rates of overall major bleeding but with an increase of non-procedure-related bleeding.